drugset / Trial / NCT00983268
Capecitabine, Vorinostat, and Radiation Therapy in Treating Patients With Nonmetastatic Pancreatic Cancer
Phase 1
Completed
21 enrolled
Vanderbilt-Ingram Cancer Center
National Cancer Institute (NCI) · collabNational Comprehensive Cancer Network · collab
NaSingle-groupOpen-labelTreatment
Summary
RATIONALE: Drugs used in chemotherapy, such as capecitabine, work in different ways to stop the growth of tumor cells, either by killing the cells or by stopping them from dividing. Vorinostat may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth. Radiation therapy uses high energy x-rays to kill tumor cells. Giving capecitabine and vorinostat together with radiation therapy may kill more tumor cells. PURPOSE: This phase I trial is studying the side effects and best dose of vorinostat when given together with capecitabine and radiation therapy in treating patients with nonmetastatic pancreatic cancer.
Timeline
- Start
- 2009-10
- Primary completion
- 2013-02
- Completion
- 2013-02
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Capecitabine | Small molecule | 1000 mg | Oral |
| Subject | Vorinostat | Small molecule | 100 mg | Oral |
| Subject | Vorinostat | Small molecule | 200 mg | Oral |
| Subject | Vorinostat | Small molecule | 300 mg | Oral |
| Subject | Vorinostat | Small molecule | 400 mg | Oral |